5427-29-2

Basic information

• Product Name: methyl 2-hydroxy-4-phenylmethoxy-benzoate
• Synonyms: methyl 2-hydroxy-4-phenylmethoxy-benzoate
• CAS NO: 5427-29-2
• Molecular Formula: C₁₅H₁₄O₄
• Molecular Weight: 258.27
• Mol File: 5427-29-2.mol
• Article Data: 31

Chemical Properties

• Melting Point: 102-104 °C
• Boiling Point: 404.8°C at 760 mmHg
• Flash Point: 150.7°C
• Appearance: /
• Density: 1.227g/cm³
• Vapor Pressure: 3.94E-07mmHg at 25°C
• Refractive Index: 1.59
• Solubility: Chloroform; Acetone
• PKA: 9.38±0.10(Predicted)
• CAS DataBase Reference: methyl 2-hydroxy-4-phenylmethoxy-benzoate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 2-hydroxy-4-phenylmethoxy-benzoate(5427-29-2)
• EPA Substance Registry System: methyl 2-hydroxy-4-phenylmethoxy-benzoate(5427-29-2)

Safety Data

• Hazardous Substances Data: 5427-29-2(Hazardous Substances Data)

Usage

Description

Methyl 2-hydroxy-4-phenylmethoxy-benzoate, also known as 2-hydroxy-4-(phenylmethoxy)benzoic acid methyl ester, is an organic compound that serves as a crucial intermediate in the synthesis of various pharmaceutical compounds. It is characterized by its ester functional group and aromatic ring structure, which contribute to its reactivity and potential applications in the chemical and pharmaceutical industries.

Uses

Used in Pharmaceutical Synthesis:
Methyl 2-hydroxy-4-phenylmethoxy-benzoate is used as an intermediate in the synthesis of 4-Hydroxy Flecainide (H942485), which is an analogue of Flecainide (F390000). Flecainide is a Class I antiarrhythmic agent used to treat various types of arrhythmias, including atrial fibrillation and ventricular tachycardia. The ester group in methyl 2-hydroxy-4-phenylmethoxy-benzoate plays a vital role in the synthesis process, allowing for the formation of the desired pharmaceutical compound with potential therapeutic benefits.
In the pharmaceutical industry, methyl 2-hydroxy-4-phenylmethoxy-benzoate is used as a key building block for the development of new drugs and therapeutic agents. Its unique chemical structure allows for further functionalization and modification, enabling the creation of novel molecules with improved pharmacological properties and enhanced efficacy.
Additionally, the compound may also find applications in other industries, such as the chemical industry, where it can be used as a starting material for the synthesis of various specialty chemicals, dyes, and other related products. Its versatility and reactivity make it a valuable asset in the development of new materials and technologies.

InChI:InChI=1/C15H14O4/c1-18-15(17)13-8-7-12(9-14(13)16)19-10-11-5-3-2-4-6-11/h2-9,16H,10H2,1H3

Upstream product

• 2150-47-2 methyl 2,4-dihydroxybenzoate 
• 22393-62-0 BnBr 
• 89-86-1 4-hydroxysalicylic acid 
• 100-51-6 benzyl alcohol 
• 422566-44-7 methyl 4-benzyloxy-2-methoxymethyloxybenzoate 
• 1026824-07-6 methyl 4-benzyloxy-2-(4-methoxy-benzyloxy)benzoate 
• 85593-76-6 methyl 2,4-bis(benzyloxy)benzoate 
• 741698-99-7 methyl 4-benzyloxy-2-isopropoxybenzoate 
• 100-39-0 benzyl bromide 
• 584-08-7 potassium carbonate 
• 100-44-7 benzyl chloride 

Downstream Products

• 28478-45-7 methyl 4-benzyloxy-2-methoxybenzoate 
• 412339-25-4 4-benzyloxy-salicylalcohol 
• 741698-99-7 methyl 4-benzyloxy-2-isopropoxybenzoate 
• 422566-44-7 methyl 4-benzyloxy-2-methoxymethyloxybenzoate 
• 1026824-07-6 methyl 4-benzyloxy-2-(4-methoxy-benzyloxy)benzoate 
• 1381865-06-0 C₂₃H₂₀O₃ 
• 1381865-07-1 C₂₅H₂₀Cl₂O₄ 
• 1381865-08-2 C₂₅H₂₂O₄ 
• 1381865-09-3 C₂₅H₂₂F₂O₃ 
• 1381865-10-6 C₁₈H₁₆F₂O₃ 
• 1381864-81-8 C₂₈H₂₃F₂NO₃ 
• 941320-15-6 C₃₈H₄₂O₁₁ 
• 1027951-65-0 4-Benzyloxy-2-(4-isopropyl-benzyloxy)-benzoic acid methyl ester 
• 170281-80-8 4-Benzyloxy-2-(4-chloro-benzyloxy)-benzoic acid methyl ester 

Relevant articles and documents

BENZOATE COMPOUND

The present invention provides a benzoic acid ester compound that has an enteropeptidase inhibitory effect, and use of the compound as a medicament for the treatment or prevention of obesity, diabetes mellitus, or the like. A compound represented by the formula (I) or a salt thereof has an enteropeptidase inhibitory effect and is useful as a medicament for the treatment or prevention of obesity, diabetes mellitus, or the like: [in the formula, each symbol is as defined in the specification].

COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR

This disclosure pertains to compounds, the preparation thereof, and the use of these compounds in the treatment of prostate cancer, including metastatic and/or castrate-resistant prostate cancer, in subjects in need thereof.

Identification of N-Hydroxycinnamamide analogues and their bio-evaluation against breast cancer cell lines

The present study demonstrates the identification of N-hydroxycinnamamide derivatives and their anticancer potential against human triple-negative breast cancer cell line MDA-MB?231, MCF-7 and non-malignant origin cell line, HEK-293 (human embryonic kidney). MTT assay was studied with HEK-293 cell line. Anticancer potential of the N-hydroxycinnamamide derivatives were compared with marked drug Tamoxifen through in vitro study. The compound numbers 3b and 3h exhibit most potent activity against antagonistic breast cancer cells (MDA-MB-231) with IC50 13μM and 5μM respectively. Compound 3h promotes DNA fragmentation and induction of apoptosis. Furthermore, loss of mitochondrial membrane potential induced by compound 3h. The major mechanism of compound 3h for anti-breast cancer activity was probably initiation of reactive oxygen species (ROS) in cancer cells thereby persuading apoptotic cell deaths in cancer cells.